Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hanover Portfolio Acquisitions
Los Angeles, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
The company's TVEMF technology, originally developed at NASA, demonstrated the ability to mobilize and expand stem cells 80-fold to therapeutic levels. Preclinical studies in athymic mice showed no tumors within 85 days of stem cell injection, and multicolor fluorescence in situ hybridization studies confirmed no chromosome damage in TVEMF-expanded stem cells 90 days after expansion[4][6].
- Therapeutic areas
- ImmunologyEndocrinologyCardiovascularNeurologyGastroenterology
- Modalities
- Electromagnetic field therapyStem cell therapy
- Industry
- Biotech
Beyond the preview
Go deeper on Hanover Portfolio Acquisitions.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hanover Portfolio Acquisitions.